Cancer predisposition syndromes as a risk factor for early second primary neoplasms after childhood cancer - A national cohort study.


Journal

European journal of cancer (Oxford, England : 1990)
ISSN: 1879-0852
Titre abrégé: Eur J Cancer
Pays: England
ID NLM: 9005373

Informations de publication

Date de publication:
03 2021
Historique:
received: 17 08 2020
revised: 17 10 2020
accepted: 23 11 2020
pubmed: 11 1 2021
medline: 21 9 2021
entrez: 10 1 2021
Statut: ppublish

Résumé

Childhood cancer patients are at increased risk of second primary neoplasms (SPNs). We assessed incidence and risk factors for early SPNs with a focus on cancer predisposition syndromes (CPSs). This cohort study used data from the Swiss Childhood Cancer Registry. We included patients with first primary neoplasms (FPNs) diagnosed before age 21 years from 1986 to 2015 and identified SPNs occurring before age 21. We calculated standardised incidence ratios (SIRs) and absolute excess risks (AERs) using Swiss population cancer incidence data, and cumulative incidence of SPNs. We calculated hazard ratios (HRs) of risk factors for SPNs using Fine and Gray competing risk regression. Among 8074 childhood cancer patients, 304 (4%) were diagnosed with a CPS and 94 (1%) developed early SPNs. The incidence of SPNs was more than 10-fold higher in childhood cancer patients than the incidence of neoplasms in the general population (SIR = 10.6, 95% confidence interval [CI]: 8.7-13.1) and the AER was 179/100,000 person-years (CI: 139-219). Cumulative incidence of SPNs 20 years after FPN diagnosis was 23% in patients with CPSs (CI: 12-41%) and 2.7% in those without (CI: 2.0-3.6%). Risk factors for SPNs were CPSs (HR = 7.8, CI: 4.8-12.7), chemotherapy (HR = 2.2, CI: 1.1-4.6), radiotherapy (HR = 1.9, CI = 1.2-2.9), haematopoietic stem cell transplantation (HR = 1.8, CI: 1-3.3), and older age (15-20 years) at FPN diagnosis (HR = 1.9, CI: 1.1-3.2). CPSs are associated with a high risk of SPNs before age 21 years. Identification of CPSs is important for appropriate cancer surveillance and targeted screening.

Sections du résumé

BACKGROUND
Childhood cancer patients are at increased risk of second primary neoplasms (SPNs). We assessed incidence and risk factors for early SPNs with a focus on cancer predisposition syndromes (CPSs).
PATIENTS AND METHODS
This cohort study used data from the Swiss Childhood Cancer Registry. We included patients with first primary neoplasms (FPNs) diagnosed before age 21 years from 1986 to 2015 and identified SPNs occurring before age 21. We calculated standardised incidence ratios (SIRs) and absolute excess risks (AERs) using Swiss population cancer incidence data, and cumulative incidence of SPNs. We calculated hazard ratios (HRs) of risk factors for SPNs using Fine and Gray competing risk regression.
RESULTS
Among 8074 childhood cancer patients, 304 (4%) were diagnosed with a CPS and 94 (1%) developed early SPNs. The incidence of SPNs was more than 10-fold higher in childhood cancer patients than the incidence of neoplasms in the general population (SIR = 10.6, 95% confidence interval [CI]: 8.7-13.1) and the AER was 179/100,000 person-years (CI: 139-219). Cumulative incidence of SPNs 20 years after FPN diagnosis was 23% in patients with CPSs (CI: 12-41%) and 2.7% in those without (CI: 2.0-3.6%). Risk factors for SPNs were CPSs (HR = 7.8, CI: 4.8-12.7), chemotherapy (HR = 2.2, CI: 1.1-4.6), radiotherapy (HR = 1.9, CI = 1.2-2.9), haematopoietic stem cell transplantation (HR = 1.8, CI: 1-3.3), and older age (15-20 years) at FPN diagnosis (HR = 1.9, CI: 1.1-3.2).
CONCLUSION
CPSs are associated with a high risk of SPNs before age 21 years. Identification of CPSs is important for appropriate cancer surveillance and targeted screening.

Identifiants

pubmed: 33423008
pii: S0959-8049(20)31379-4
doi: 10.1016/j.ejca.2020.11.042
pii:
doi:

Substances chimiques

Antineoplastic Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

71-80

Investigateurs

Marc Ansari (M)
Maja Beck-Popovic (M)
Jean-Pierre Bourquin (JP)
Pierluigi Brazzola (P)
Jeanette Greiner (J)
Jochen Rössler (J)
Katrin Scheinemann (K)
Freimut Schilling (F)
Nicolas von der Weid (N)

Informations de copyright

Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest statement The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Nicolas Waespe (N)

Institute of Social and Preventive Medicine, University of Bern, Switzerland; Research Platform for Pediatric Oncology and Hematology (CANSEARCH Research Platform), Department of Pediatrics, Gynecology, and Obstetrics, University of Geneva, Switzerland.

Fabiën N Belle (FN)

Institute of Social and Preventive Medicine, University of Bern, Switzerland; Centre universitaire de médecine générale et santé publique (UNISANTÉ), Institute of Social and Preventive Medicine (IUMSP), University of Lausanne, Switzerland.

Shelagh Redmond (S)

Institute of Social and Preventive Medicine, University of Bern, Switzerland.

Christina Schindera (C)

Institute of Social and Preventive Medicine, University of Bern, Switzerland; Division of Pediatric Oncology/ Hematology, University Children's Hospital Basel, University of Basel, Switzerland.

Ben D Spycher (BD)

Institute of Social and Preventive Medicine, University of Bern, Switzerland.

Jochen Rössler (J)

Division of Pediatric Hematology and Oncology, University Children`s Hospital Bern, Switzerland.

Marc Ansari (M)

Research Platform for Pediatric Oncology and Hematology (CANSEARCH Research Platform), Department of Pediatrics, Gynecology, and Obstetrics, University of Geneva, Switzerland; Department of Pediatrics, Pediatric Oncology and Hematology Unit, Geneva University Hospitals, Geneva, Switzerland.

Claudia E Kuehni (CE)

Institute of Social and Preventive Medicine, University of Bern, Switzerland; Division of Pediatric Hematology and Oncology, University Children`s Hospital Bern, Switzerland. Electronic address: claudia.kuehni@ispm.unibe.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH